Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) Net Margin (2018 - 2023)

Denali Therapeutics (DNLI) has disclosed Net Margin for 6 consecutive years, with 7841.59% as the latest value for Q3 2023.

  • Quarterly Net Margin fell 493912.0% to 7841.59% in Q3 2023 from the year-ago period, while the trailing twelve-month figure was 33121.86% through Jun 2024, down 3308442.0% year-over-year, with the annual reading at 43.94% for FY2023, 25662.0% up from the prior year.
  • Net Margin for Q3 2023 was 7841.59% at Denali Therapeutics, down from 62.35% in the prior quarter.
  • The five-year high for Net Margin was 62.35% in Q2 2023, with the low at 7004100.0% in Q1 2021.
  • Average Net Margin over 5 years is 425192.64%, with a median of 1236.26% recorded in 2019.
  • The sharpest move saw Net Margin crashed -700250096bps in 2021, then soared 700394220bps in 2022.
  • Over 5 years, Net Margin stood at 1236.26% in 2019, then surged by 50bps to 619.91% in 2020, then plummeted by -158bps to 1600.53% in 2021, then skyrocketed by 38bps to 986.78% in 2022, then crashed by -695bps to 7841.59% in 2023.
  • According to Business Quant data, Net Margin over the past three periods came in at 7841.59%, 62.35%, and 312.4% for Q3 2023, Q2 2023, and Q1 2023 respectively.